[Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events]

Med Clin (Barc). 2014 May 20;142(10):469-70. doi: 10.1016/j.medcli.2013.07.017. Epub 2013 Oct 8.

[Article in Spanish]

Authors

Dolors Grados¹, Melania Martínez-Morillo², Susana Holgado², Alba Erra³

Affiliations

¹ Servicio de Reumatología, Hospital de Sant Rafael, Barcelona, España. Electronic address: [email protected].
² Servicio de Reumatología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España.
³ Servicio de Reumatología, Hospital de Sant Rafael, Barcelona, España.

PMID: 24120108
DOI: 10.1016/j.medcli.2013.07.017

No abstract available

Publication types

Evaluation Study
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Bone Density Conservation Agents / adverse effects*
Bone Density Conservation Agents / therapeutic use
Diphosphonates / adverse effects*
Diphosphonates / therapeutic use
Humans
Imidazoles / adverse effects*
Imidazoles / therapeutic use
Male
Middle Aged
Osteitis Deformans / drug therapy*
Retrospective Studies
Treatment Outcome
Zoledronic Acid

Substances

Bone Density Conservation Agents
Diphosphonates
Imidazoles
Zoledronic Acid